MeSeI exhibits a weak inhibitory activity against monoamine oxidase MAO-A and MAO-B (IC50=198.8 µM). MeSeI regulates dopamine receptor D2 and norepinephrine receptor alpha2, beta1, and exhibits antidepressant-like effect in mice. MeSeI is orally active[1].